Neogenomics, Inc.
NEO
$10.10
-$0.44-4.18%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 10.57% | 10.44% | 11.97% | 13.86% | 12.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.57% | 10.44% | 11.97% | 13.86% | 12.15% |
| Cost of Revenue | 7.71% | 3.68% | 5.72% | 10.15% | 7.43% |
| Gross Profit | 14.31% | 20.17% | 21.04% | 19.44% | 18.94% |
| SG&A Expenses | 9.75% | 2.75% | 7.32% | 10.55% | -3.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.79% | 4.53% | 6.42% | 10.02% | 2.39% |
| Operating Income | 7.35% | 36.23% | 23.95% | 7.31% | 42.74% |
| Income Before Tax | -5.51% | 16.79% | 28.61% | 17.91% | 40.11% |
| Income Tax Expenses | 16.25% | 94.89% | 83.76% | 78.80% | 66.16% |
| Earnings from Continuing Operations | -6.97% | 4.41% | 23.38% | 12.13% | 36.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.97% | 4.41% | 23.38% | 12.13% | 36.85% |
| EBIT | 7.35% | 36.23% | 23.95% | 7.31% | 42.74% |
| EBITDA | 90.44% | 199.31% | 73.25% | 21.15% | 110.11% |
| EPS Basic | -5.89% | 5.36% | 24.01% | 12.87% | 37.44% |
| Normalized Basic EPS | 2.62% | 45.06% | 26.47% | 13.65% | 52.84% |
| EPS Diluted | -5.89% | 6.67% | 22.72% | 14.16% | 37.44% |
| Normalized Diluted EPS | 2.62% | 45.06% | 26.47% | 13.65% | 52.84% |
| Average Basic Shares Outstanding | 0.98% | 1.01% | 0.84% | 0.87% | 0.97% |
| Average Diluted Shares Outstanding | 0.98% | 1.01% | 0.84% | 0.87% | 0.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
